Last reviewed 2026-04-23 · How we verify

Sotagliflozin Low Dose

Sotagliflozin inhibits both SGLT2 and SGLT1 transporters to reduce glucose reabsorption in the kidneys and intestines, lowering blood glucose levels.

Sotagliflozin inhibits both SGLT2 and SGLT1 transporters to reduce glucose reabsorption in the kidneys and intestines, lowering blood glucose levels. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus (in combination with insulin).

At a glance

Mechanism of action

Sotagliflozin is a dual SGLT1/SGLT2 inhibitor that works by blocking sodium-glucose cotransporters in the proximal tubule of the kidney and in the small intestine. By inhibiting SGLT2, it increases urinary glucose excretion; by inhibiting SGLT1, it reduces intestinal glucose absorption. This dual mechanism provides additional glycemic control compared to SGLT2-only inhibitors.

Approved indications

• Type 2 diabetes mellitus
• Type 1 diabetes mellitus (in combination with insulin)

Common side effects

• Genital mycotic infections
• Urinary tract infections
• Nausea
• Diarrhea
• Diabetic ketoacidosis

Key clinical trials

• CKM For Safe Use of SGLT2i in Type 1 Diabetes (PHASE3)
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sotagliflozin Low Dose CI brief — competitive landscape report
• Sotagliflozin Low Dose updates RSS · CI watch RSS
• University of California, San Diego portfolio CI